Abstract
Alexion Pharmaceuticals has struck two new partnerships to develop biologic drugs that can be administered subcutaneously for immune system diseases. Alexion will pay Affibody $25 million to codevelop an antibody-like protein therapy for IgG-mediated autoimmune conditions. Separately, Alexion will pay Zealand Pharma $25 million and make a $15 million investment in the firm toward peptide therapies for diseases related to the innate immune system. Affibody and Zealand both could earn more than $600 million in milestone payments if the therapies are successful.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
